贝伐珠单抗+埃克替尼治疗中晚期非小细胞肺癌的临床有效率研究  

Study on the Clinical Effectiveness of Bevacizumab+Icotinib in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：任云会[1] 车瑛琦[1] 李雪[1] 张丽丽[1] 李文庆[1] 孙晶波[1] REN Yunhui;CHE Yingqi;LI Xue;ZHANG Lili;LI Wenqing;SUN Jingbo(Department of Hematology and Oncology,Longnan Hospital of Daqing(Fifth Affiliated Hospital of Qiqihar Medical College),Daqing,Heilongjiang Province,163453 China)

机构地区：[1]大庆龙南医院(齐齐哈尔医学院第五附属医院)血液肿瘤科,黑龙江大庆163453

出　　处：《中外医疗》2021年第28期86-89,共4页China & Foreign Medical Treatment

摘　　要：目的研究中晚期非小细胞肺癌(NSCLC)患者行贝伐珠单抗+埃克替尼治疗效果。方法方便选取该院2019年5月-2020年8月收治的80例中晚期NSCLC患者,根据随机数表法分常规组(埃克替尼,n=40)、联合组(贝伐珠单抗+埃克替尼,n=40),比较两组疗效。结果用药前,两组生活质量、肿瘤标志物及凝血功能差异无统计学意义(P>0.05);用药后,同常规组比较,联合组生活质量评分更高,肿瘤标志物指标更低,凝血酶原时间(PT)、凝血酶时间(TT)及活化部分凝血活酶时间(APTT)指标更高,纤维蛋白原(FIB)指标更低,差异有统计学意义(P<0.05)。联合组有效率(97.50%)高于常规组(80.00%),差异有统计学意义(χ^(2)=4.507,P=0.034)。结论贝伐珠单抗+埃克替尼治疗NSCLC患者能提高疗效、控制病情,值得推崇。Objective To study the effect of bevacizumab+icotinib in patients with advanced non-small cell lung cancer(NSCLC).Methods Samples were conveniently selected from 80 patients with intermediate and advanced NSCLC admitted to the hospital from May 2019 to August 2020.According to the random number table method,they were divided into the conventional group(icotinib,n=40)and the combined group(Bevacizumab+Icotinib,n=40),comparison of the efficacy of the two groups.Results Before medication,the difference in quality of life,tumor markers and coagulation function between the two groups was not statistically significant(P>0.05);after medication,compared with the conventional group,the combined group had a higher quality of life score,lower tumor marker indicators,prothrombin time(PT),higher index of thrombin time(TT)and activated partial thromboplastin time(APTT),and lower index of fibrinogen(FIB),and the difference was statistically significant(P<0.05).The effective rate of the combined group(97.50%)was higher than that of the conventional group(80.00%),and the difference was statistically significant(χ^(2)=4.507,P=0.034).Conclusion Bevacizumab+icotinib in the treatment of NSCLC patients can improve the efficacy and control the disease,which is worthy of praise.

关 键 词：贝伐珠单抗 埃克替尼 中晚期 非小细胞肺癌 临床疗效 

分 类 号：R979.1[医药卫生—药品]